SCM
TCRR

Silverarc Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Silverarc Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-188,142
Closed -$3.09M – 113
2021
Q2 		$3.09M Buy
188,142
+32,997
+21% +$667K 1.38% 22
2021
Q1 		$3.43M Buy
155,145
+19,145
+14% +$522K 1.87% 19
2020
Q4 		$4.21M Buy
+136,000
New +$3.44M 2.44% 14

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Silverarc Capital Management's TCRR Position: Q3 2021 in Review

Silverarc Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 188,142 shares — an estimated $3.09M sold.

Silverarc Capital Management first reported a position in TCRR in Q4 2020 and held it in 3 quarters. The position peaked at $4.21M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Silverarc Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 188,142 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $3.09M.
  • Silverarc Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Silverarc Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $4.21M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.